Treatment of patients with HER2-mutant non-small cell lung cancer with pyrotinib in a phase 2 trial or compassionate use showed a favourable objective response rate, while patients treated in parallel by physician's choice in a real-world study did not.
This work was funded by the National Natural Science Foundation of China , Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer , Guangdong Provincial People’s Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province , National Natural Science Foundation of China and the High-Level Hospital Construction Project . Medical writing assistance and figure processing for this manuscript were provided by W. Shi and H. Dong of Jiangsu Hengrui Pharmaceuticals.
Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital , Southern Medical University, Guangzhou, China Hai-Yan Tu, Xue-Wu Wei, Hong-Hong Yan, Chong-Rui Xu, Ming-Ying Zheng, Yang-Si Li, Zhen Wang, Xiao-Yan Bai, An-Na Li, Yue-Li Sun, Jie Huang, Jia-Xin Lin, E. E.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer - Nature ChemistryThree-protein conjugates, which have so far been produced using protein-engineering strategies, can now be generated using a chemical approach that enables the addition of small-molecule functionality. Checkpoint inhibitory T cell engagers (CiTEs) were assembled and shown to have enhanced in vitro potency compared to a traditional T cell engager.
Read more »
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial - Nature MedicineTrastuzumab deruxtecan, an anti-HER2–drug conjugate, exhibits the highest objective response rate in patients with HER2-overexpressing metastatic breast cancer, but clinical activity is also observed in patients with HER2-low or non-expressing tumors, potentially pointing to additional determinants of drug efficacy.
Read more »
First Hijabi footballer and first Arab team debut in women’s World CupHistoric Moment at FIFA Women’s World Cup: Nouhaila Benzina makes history as the first hijabi player, representing Morocco’s first-ever women’s team from the Middle East & North Africa
Read more »
Hot 100 First-Timers: NoCap Scores First Appearance With Rylo Rodriguez Team-Up ‘Thang for You’Congrats, NoCap! He earns his first entry on the Hot100 as his Rylo Rodriguez team-up 'Thank for You' debuts at No. 96. 🔥
Read more »
Paris 1951: The birth of CERN - NatureStarting this week with François de Rose's reflections on the 1951 conference that created the CERN particle physics laboratory, a new Essay series recalls six scientific meetings that changed the world. Written by someone who was right there, each piece describes what it was like to experience such a momentous event, and looks back on its lasting legacy.
Read more »